LENALIDOMIDE STRAGEN 7.5 mg, hard capsule 21 capsules
Active ingredients: LÉNALIDOMIDE
Commercialized according to BDPMDispensing in France: Prescription only
Hard capsule21 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- LENALIDOMIDE STRAGEN 7,5 mg, gélule
- Pharmaceutical form
- gélule
- Route of administration
- orale
- Presentation description
- plaquette(s) OPA : polyamide orienté aluminium PVC-Aluminium de 21 gélule(s)
- Marketing authorisation holder
- STRAGEN-FRANCE
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 24 Feb 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
67764717CIP73020494CIP133400930204948Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| LÉNALIDOMIDEgélule | 7,5 mg · une gélule | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
Group of similar medicines: LENALIDOMIDE 7,5 mg - REVLIMID 7,5 mg, gélule